Company Spotlights

Beren Therapeutics: A biotech targeting the root cause of a rare childhood disease

11 Aug, 20263+ minutes

Beren Therapeutics: A biotech targeting the root cause of a rare childhood disease

More than 300 million people around the world live with a rare disease, and around 95% of those conditions still have no approved treatment. Most are genetic, and a striking number begin in childhood. Progress can feel painfully slow, but every so often a company comes along that shifts the outlook for patients who have spent years waiting for options. This month, we're spotlighting one of them: Beren Therapeutics.

Beren is focused on Niemann-Pick disease type C, usually shortened to NPC, a rare inherited condition that affects roughly one in 120,000 babies. NPC is sometimes described as "childhood Alzheimer's," because it gradually affects a child's ability to move, speak and remember as fatty molecules build up inside their cells and disrupt how the brain works.

It's a hard diagnosis for any family to receive, and for children with the infantile-onset form, it progresses especially quickly. That is precisely why Beren works with such urgency, and why their progress means so much to the families counting on it.

Beren Therapeutics and their mission

Beren is a founder-led, clinical-stage biotech based in Thousand Oaks, California, developing its lead treatment through its subsidiary, Mandos LLC. The company is built around one clever piece of cell biology: cholesterol trafficking, the system your cells use to move cholesterol and fats to where they're needed. In NPC, that system doesn't work as it should, so these substances build up where they shouldn't, and the damage to the brain and body follows from there.

What sets Beren apart isn't only the science, but the way the company itself is built. Beren is a public benefit corporation, and the "P.B.C." in its name is a legal status rather than a marketing line.

A PBC is a for-profit business that is legally required to balance its social mission with its profits, and its directors are protected when they choose to put patients, caregivers, and clinicians first. For a company working on a disease this rare, where patient numbers alone will never make it an obvious commercial bet, that structure says a great deal about what guides their decisions.

That mission is backed by serious investment, too. In 2026, Beren secured $300 million in financing to help move its treatment toward the patients who need it and to support long-term care for the NPC community.

Their lead treatment: adrabetadex

Beren's lead treatment is adrabetadex, and the idea behind it is simple. If NPC is caused by cholesterol getting trapped inside cells, adrabetadex is designed to help free it up. It belongs to a group of molecules called cyclodextrins, which can attach to cholesterol and carry it out of the cells where it has collected. By getting that flow moving again, the treatment goes after the root cause of the disease, rather than only easing the symptoms it produces.

That's an important distinction. A couple of therapies are already approved to help manage the neurological symptoms of NPC, but adrabetadex is designed to target the underlying cause itself. Beren's application focuses on infantile-onset NPC, the form that strikes earliest and hardest, and if the treatment is approved, it would be the first to work in this way.

The evidence so far is encouraging. A survival analysis submitted to regulators showed that children treated with adrabetadex lived longer than the natural course of the disease would predict, alongside signs of slower progression and supportive data from biomarkers (measurable biological signals that show whether a treatment is having an effect).

The treatment has generally been well tolerated. Because of this, the FDA granted adrabetadex Breakthrough Therapy Designation, a status reserved for treatments that could offer a real step forward where options are limited.

A decision is now close. The FDA accepted Beren's application in early 2026 and is reviewing it under Priority Review, with a target date of 17 November 2026. In practical terms, families could find out by the end of this year whether the first treatment aimed at the cause of NPC is on its way.

Potential impact

The impact reaches far beyond the first children treated. NPC affects families across the globe, and progress on one rare disease often drives research and funding for others. It shows that conditions this rare are still worth pursuing. Beren has already begun expanding internationally, a hint of how far that reach could grow.

At its heart, Beren's founding belief is a straightforward one: how rare your condition is shouldn't decide whether you can access medicine. By pairing patient-first science with a structure that keeps patients at the center of every decision, the company is working to give families facing an NPC diagnosis the two things this disease has too often taken from them: time, and hope.

If you're working in the biotechnology space and looking for your next role, or to expand an important team, feel free to contact us today. Our industry experts will be able to get the process started for you.

Quick CV Drop Off